TrialAnnals of hematology2025

Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial.

Shenmiao Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.